QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kulanthaivel, P. Articles by Ehlhardt, W. J. Search for Related Content PubMed PubMed Citation Articles by Kulanthaivel, P. Articles by Ehlhardt, W. J.

SELECTIVE REDUCTION OF N-OXIDES TO AMINES: APPLICATION TO DRUG METABOLISM

Lilly Research Laboratories, Indianapolis, Indiana

Phase I oxidative metabolism of nitrogen-containing drug molecules to their corresponding N-oxides is a common occurrence. There are instances where liquid chromatography/tandem mass spectometry techniques are inadequate to distinguish this pathway from other oxidation processes, including C-hydroxylations and other heteroatom oxidations, such as sulfur to sulfoxide. Therefore, the purpose of the present study was to develop and optimize an efficient and practical chemical method to selectively convert N-oxides to their corresponding amines suitable for drug metabolism applications. Our results indicated that efficient conversion of N-oxides to amines could be achieved with TiCl₃ and poly(methylhydrosiloxane). Among them, we found TiCl₃ to be a facile and easy-to-use reagent, specifically applicable to drug metabolism. There are a few reports describing the use of TiCl₃ to reduce N-O bonds in drug metabolism studies, but this methodology has not been widely used. Our results indicated that TiCl₃ is nearly as efficient when the reductions were carried out in the presence of biological matrices, including plasma and urine. Finally, we have shown a number of examples where TiCl₃ can be successfully used to selectively reduce N-oxides in the presence of sulfoxides and other labile groups.

This article has been cited by other articles:

				C. Prakash, W. Wang, T. O'Connell, and K. A. Johnson CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance Drug Metab. Dispos., October 1, 2008; 36(10): 2093 - 2103. [Abstract] [Full Text] [PDF]

				C. L. Shaffer, M. Gunduz, T. N. O'Connell, R. S. Obach, and S. Yee BIOTRANSFORMATION OF A GABAA RECEPTOR PARTIAL AGONIST IN SPRAGUE-DAWLEY RATS AND CYNOMOLGUS MONKEYS: IDENTIFICATION OF TWO UNIQUE N-CARBAMOYL METABOLITES Drug Metab. Dispos., November 1, 2005; 33(11): 1688 - 1699. [Abstract] [Full Text] [PDF]

				K. A. Johnson and C. Prakash METABOLISM, EXCRETION, AND PHARMACOKINETICS OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID, AN EP2 RECEPTOR-SELECTIVE PROSTAGLANDIN E2 AGONIST, IN MALE AND FEMALE SPRAGUE-DAWLEY RATS Drug Metab. Dispos., August 1, 2005; 33(8): 1191 - 1201. [Abstract] [Full Text] [PDF]